UPClytics
Alle Fälle anzeigen

UPC CFI 231/2024

30. Mai 2024·EP3831283 · ANALYTE SENSOR DEVICES, CONNECTIONS, AND METHODS

Verfahrensdetails
Status
Case Closed (Patent wie erteilt aufrechterhalten)
Verfahrensart
Nichtigkeit
Kategorie
Hauptnichtigkeitsklage
Parteien
Kläger
Vertreter
Beklagte
Vertreter
Division
Paris CD
Technologie
  • Instruments
    Medical technology
Sprache
English
Erste Entscheidung
21. Juli 2025
Im Vergleich
Die Bilanz des Gerichts für diese Art von Verfahren, gezählt in erstinstanzlichen Entscheidungen. Eine Zahl in Klammern gibt an, auf wie vielen Entscheidungen eine Quote beruht.
Patent nichtigMedian Tage bis zur ersten Entscheidung
Gesamt-UPC37% (34/91)124
Paris CDGesperrtGesperrt
Richter Paolo CatallozziGesperrtGesperrt
Richter Tatyana ZhilovaGesperrtGesperrt
Richter Renaud FulconisGesperrtGesperrt

Vor dem UPC: Sibio Technology Limited (15 Verfahren)·Abbott Group (67 Verfahren)

Entscheidungen
  • 2025-07-21
    Revocation ActionÖffentlich

    Zusammenfassung: Decision of the Paris Central Division dismissing the revocation action by Sibio Technology Limited against Abbott Diabetes Care Inc. concerning EP 3 831 283 B1 (glucose monitoring device / CGM sensor). All grounds for revocation (lack of novelty and inventive step) failed. The patent is maintained as granted. Abbott (defendant/patentee) awarded costs. Key headnotes: novelty and inventive step are separate grounds and cannot be combined against the same prior art; grounds for revocation of dependent claims must be stated from the outset; Rule 75(3) RoP does not apply when a counterclaim for revocation in a subsequent infringement action is filed after the oral hearing in an earlier revocation action.

    Rechtsfragen anzeigen (5)
    • Revocation action - novelty and inventive step as separate grounds
    • Grounds for revocation of dependent claims
    • Late-filed arguments
    • Rule 75(3) RoP interaction with parallel proceedings
    • CGM sensor patent validity
DokumenttitelDatumÖffentlich
DecisionOutcome2025-07-21Nicht öffentlich
final decision2025-07-21Öffentlich
Hearing Reference2025-06-05Nicht öffentlich
Hearing Reference2025-06-05Nicht öffentlich
Outcome of the Order2025-05-28Nicht öffentlich
procedural order2025-05-28Öffentlich
Receipt2025-05-05Nicht öffentlich
Application pursuant to Rule 92025-05-02Nicht öffentlich
Order allowing for comments2025-05-02Nicht öffentlich
Outcome of the Order2025-04-14Nicht öffentlich
Zusammenfassung in einfacher Sprache

Sibio Technology Limited (Hong Kong) filed a revocation action against Abbott Diabetes Care Inc. (US) seeking to revoke EP 3 831 283 B1, a patent for continuous glucose monitoring sensor devices and connections. The Paris Central Division dismissed the revocation action in full, maintaining the patent as granted: Sibio's novelty attack over WO'896 was inadmissible for failure to provide a separate novelty analysis, and the inventive step attack combining WO'896 and US'440 failed because US'440 provides no pointer to the dramatic design change needed to arrive at the claimed recess-and-opening configuration.

Angenommene Argumente
Was das Gericht akzeptiert hat — nach Partei.
  • Patent EP 3 831 283 B1 is novel over WO'896 (closest prior art for inventive step) because WO'896 does not disclose the recess in a bottom exterior surface with the connect support received through a distal-facing opening

    BeklagterRechtsgrundlage: Art. 54 EPC

    Hinweis: Court found that WO'896 does not anticipate the distinguishing features 1.4 and 1.5 of claim 1.

  • Claim 1 involves an inventive step: US'440 provides no pointer to motivate or enable the dramatic design change needed to arrive at the claimed invention from WO'896

    BeklagterRechtsgrundlage: Art. 56 EPC; problem-solution approach

    Hinweis: Court applied problem-solution: regardless of how the technical problem is formulated, US'440 would not motivate the skilled person to modify WO'896 in the required manner because it does not disclose the relevant distinguishing features and no pointer exists for the dramatic design change required.

  • Sibio's second line of inventive step argumentation (re-mapping top/base of housing) is inadmissible as late-filed

    BeklagterRechtsgrundlage: R. 75 RoP

    Hinweis: Court upheld Abbott's admissibility objection to the second line of argumentation first raised in Sibio's Reply.

  • Sibio's novelty challenge over WO'896 is inadmissible: merely referencing a document for novelty/inventive step in general terms without a detailed novelty analysis is insufficient

    BeklagterRechtsgrundlage: Art. 65 UPCA; R. 206 RoP

    Hinweis: Court held that lack of novelty and lack of inventive step are separate grounds that cannot be absorbed by each other; a detailed analysis only for inventive step does not establish that novelty is separately challenged.

Zurückgewiesene Argumente
Was das Gericht nicht akzeptiert hat — und warum.
  • Claim 1 of EP 3 831 283 B1 lacks novelty over WO'896

    KlägerRechtsgrundlage: Art. 54 EPC; R. 206 RoP

    Begründung: Admissibility: Sibio only provided a detailed analysis with respect to inventive step over WO'896; merely indicating a document will be used for novelty and/or inventive step without specific novelty analysis is insufficient to establish a novelty challenge. Substantively also not established.

  • Claim 1 lacks inventive step starting from WO'896 combined with US'440

    KlägerRechtsgrundlage: Art. 56 EPC

    Begründung: US'440 provides no incentive for the skilled person to make the dramatic design change required; no pointer identified for arriving at the distinguishing features 1.4 and 1.5.

  • R. 75(3) RoP bars a new counterclaim for revocation concerning the same patent after an earlier revocation action

    BeklagterRechtsgrundlage: R. 75(3) RoP; Preamble to RoP para. 4

    Begründung: R. 75(3) RoP does not apply when a counterclaim for revocation in a subsequent infringement action before a Local Division is filed after the oral hearing in an earlier Central Division revocation action; flexibility and efficiency principle prevails.

Herangezogener Stand der Technik
Zitierte Schriften und die Rolle, die sie gespielt haben.
  • WO'896 (glucose monitoring prior art)Erfindungsmüh-Kombination
  • US'440 (glucose sensor assembly prior art)Erfindungsmüh-Kombination
Hinweise zur Anspruchsauslegung

Claim 1 of EP 3 831 283 B1 (analyte sensor for continuous glucose monitoring) was construed with attention to features 1.4 (recess in a bottom exterior surface) and 1.5 (connect support received through a distal-facing opening into the recess). The mapping proposed by Sibio in the alternative (treating the top of the housing as the base portion) was held unreasonable and inadmissible.